Microbiotix Home Page

Who We Are

We are a small molecule, anti-infective company.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the discovery and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development.

Microbiotix has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant Gram-positive and Gram-negative bacteria. In addition to a Gram-positive antibiotic (MBX500), our most advanced antiviral compounds target cytomegalovirus (CMV) ( MBX400) and are in preclinical development.

Microbiotix also has an active biodefense program, focused on novel therapeutics for Bacillus anthracis and Burkholderia pseudomallei and is also actively involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance.

What's New

Click on the book to the left of any item below for more information.

9/1/2009 Microbiotix received an NIAID STTR Phase II grant to develop novel chemical classes of helicase or primase inhibitors for anti-bacterial therapy.

9/1/2009 Microbiotix receives an NIAID SBIR Phase I grant to develop therapeutic agents for the treatment of Ebola infections.

7/15/2009 Microbiotix receives an NIAID SBIR Phase I grant to discover and characterize inhibitors of a key virulence factor involved in dissemination and immune system evasion by septicemic bacterial infections.

7/1/2009 Microbiotix receives a NIAID U01 grant to develop a novel bis-indole chemical series for therapeutic applications in biodefense and emerging infections.

2/11/2009 Microbiotix receives an NIAID SBIR Phase I grant to develop a novel series of purine nucleoside analogs for therapeutic efficacy against emerging infectious disease agents HHV-6 and HHV-8.

9/1/2008 Microbiotix receives an SBIR Phase II Renewal grant to develop an expanded IV preclinical biological profile of a second generation methylenecyclopropane for treatment of CMV infections and to file an Investigational New Drug (IND) application.

8/15/2008 Microbiotix receives an NIAID SBIR Phase I grant to discover and characterize new agents inhibiting the entry of influenza virus into host cells.